Apex Trader Funding (ATF) - News
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported second-quarter adjusted EPS of $11.56, up 13% year-over-year, beating the consensus of $10.61.
The company reported sales of $3.55 billion, up 12%, beating the consensus of $3.38 billion.
Also Read: Europe Approves Sanofi/Regeneron’s Dupixent for ‘Smoker’s Lungs’ A Month After US FDA Asks For Data.
“Regeneron had a strong quarter, with total revenue up 12% driven by notable growth for EYLEA HD, Dupixent, and Libtayo,” said Leonard S. Schleifer, Board co-Chair, President and